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Abstract Morphine-3- and morphine-6-glucuronide are mor-
phine’s major metabolites. As morphine-6-glucuronide produces
stronger analgesia than morphine, we investigated the effects of
acute and chronic morphine glucuronides on adenylyl cyclase
(AC) activity. Using COS-7 cells cotransfected with representa-
tives of the nine cloned AC isozymes, we show that AC-I and V
are inhibited by acute morphine and morphine-6-glucuronide, and
undergo superactivation upon chronic exposure, while AC-II is
stimulated by acute and inhibited by chronic treatment.
Morphine-3-glucuronide had no effect. The weak opiate agonists
codeine and dihydrocodeine are also addictive. These opiates, in
contrast to their 3-O-demethylated metabolites morphine and
dihydromorphine (formed by cytochrome P450 2D6), demon-
strated neither acute inhibition nor chronic-induced superactiva-
tion. These results suggest that metabolites of morphine
(morphine-6-glucuronide) and codeine/dihydrocodeine (mor-
phine/dihydromorphine) may contribute to the development of
opiate addiction.
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1. Introduction
Opiate agonists are the drugs of choice for the treatment of
moderate and severe pain, although their use is limited due to
side e¡ects, including the development of tolerance, respira-
tory depression and constipation. Pharmacological studies
have de¢ned three types of opioid receptors, termed W, N
and U, which di¡er in their a⁄nity for various opioid ligands,
their distribution in the nervous system, and their physiolog-
ical and behavioral pro¢les [1,2]. The three opioid receptors
are members of the seven-transmembrane domain GTP-bind-
ing protein (G protein)-coupled receptor superfamily. Activa-
tion of these receptors inhibits the activity of adenylyl cyclase
(AC) via the Gi=o type of G proteins. Yet, we and others have
shown that when these and several other Gi=o-coupled recep-
tors (e.g. D2-dopaminergic, m2- and m4-muscarinic, K2-adren-
ergic, somatostatin) are chronically activated, there is an in-
crease in cAMP accumulation, which is particularly apparent
upon withdrawal of the inhibitory agonist [3^11]. This phe-
nomenon has been referred to as AC sensitization, or super-
activation, and is believed to represent a possible biochemical
substrate for the development of drug tolerance and depen-
dence, commonly observed upon prolonged exposure to opi-
ate drugs [3,12].
The opiate agonist morphine is metabolized in humans to
morphine-3- and morphine-6-glucuronides. While it was pre-
viously considered that glucuronide metabolites are pharma-
cologically inactive and that their formation is a mechanism
for the detoxi¢cation and elimination of the parent com-
pound, it is now recognized that their formation might have
important pharmacological implications. In animal experi-
ments, both glucuronides have been shown to in£uence the
analgesic e¡ects of morphine. Morphine-6-glucuronide exhib-
ited both a higher analgesic potency [13^15] and an increased
physical dependence [15] compared with morphine. These re-
sults appear to be in contrast to binding studies in which
morphine-6-glucuronide and morphine displayed comparable
binding to the W-receptor [13,16]. On the other hand, mor-
phine-3-glucuronide showed only a poor a⁄nity to the W-re-
ceptor and even antagonized morphine’s analgesic e¡ect [17].
Indeed, recent investigations point to a new binding site for
morphine-6-glucuronide, di¡erent than the known W-opioid
receptor type 1 (MOR-1) [18,19]. However, the role of
MOR-1 in mediating the acute and chronic signaling elicited
by opiates, such as morphine-6-glucuronide and heroin, has
not yet been systematically investigated. It was therefore of
interest to determine whether the acute and chronic activation
of the W-receptor with such compounds in transfected Chinese
hamster ovary (CHO) and African green monkey kidney
(COS-7) cells would yield results similar to those observed
with morphine. Moreover, we have previously shown that
not all of the nine isozymes of AC which have been identi¢ed
to date [20,21] behave identically with respect to regulation by
morphine [11]. It was therefore of interest to study the regu-
lation of these AC isozymes by morphine metabolites and
derivatives.
Besides the strong opiate morphine, the weak and moderate
opiates codeine and dihydrocodeine (see formulas in Fig. 1)
are used in the treatment of mild to moderate pain, as well as
in cough treatment. Prescription analgesics, including these
opiates, are among the major classes of drugs prescribed
and used worldwide [22]. Codeine and dihydrocodeine, alone
or in combination with other drugs, are among the most
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widely abused prescription drugs [22,23]. While these drugs
present only weak binding to the W-receptor (probably due
to the blockage of the 3P OH position), they are metabolized
by the enzyme cytochrome P450 2D6 (CYP2D6) to form the
strong opiates morphine and dihydromorphine [24,25] (Fig.
1). Consequently, the question arises of whether it are codeine
and dihydrocodeine themselves, or rather their 3-O-demethyl-
ated metabolites morphine and dihydromorphine, that lead to
addiction and withdrawal symptoms. We therefore investi-
gated the e¡ects of codeine and dihydrocodeine in comparison
to the e¡ects of morphine and dihydromorphine on AC ac-
tivity in CHO cells stably transfected with the MOR.
2. Materials and methods
2.1. Materials
[3H-2]Adenine (18.0 Ci/mmol) was purchased from American Ra-
diolabeled Chemicals (St. Louis, MO, USA). Morphine and dihydro-
morphine were obtained from the National Institute of Drug Abuse,
Research Technology Branch (Rockville, MD, USA), and naloxone
was purchased from Research Biochemical International (Natick,
MA, USA). Morphine-3- and morphine-6-glucuronide, codeine and
3-ethylmorphine, as well as forskolin (FS), cAMP and thyroid-stim-
ulating hormone (TSH), were obtained from Sigma (St. Louis, MO,
USA). Dihydrocodeine was obtained from Knoll Pharma (Lud-
wigshafen, Germany). Ionomycin and the phosphodiesterase inhibi-
tors 1-methyl-3-isobutylxanthine (IBMX) and RO-20-1724 were from
Calbiochem (La Jolla, CA, USA). Tissue culture reagents were from
Life Technologies (Gaithersburg, MD, USA).
2.2. Plasmids
Plasmids containing AC cDNAs (pXMD1-AC-I, pXMD1-AC-II
and pXMD1-AC-V), as well as pXMD1-gal, rat TSH receptor in
pSG5, and rat MOR in pCMV-neo have previously been described
[11].
2.3. Transfected cells
The CHO cell line stably transfected with the rat MOR cDNA
(CHO-W) was previously described [9]. The CHO-W cells were cultured
in Dulbecco’s modi¢ed Eagle’s medium (DMEM) supplemented with
8% fetal calf serum, 2 mM glutamine, non-essential amino acids,
0.2 mg/ml G418, 100 U/ml penicillin and 100 Wg/ml streptomycin in
a humidi¢ed atmosphere consisting of 5% CO2 and 95% air at 37‡C.
Transient transfection of COS-7 cells was performed as previously
described [11]. In brief, COS-7 cells in 10-cm plates were transfected
using the DEAE-dextran chloroquine method with 1 Wg/plate of plas-
mid encoding the MOR, 2 Wg/plate of plasmid encoding either one of
the AC isozymes or pXMD1-gal (for mock DNA transfection), and,
where indicated, with 1 Wg/plate of plasmid encoding the TSH recep-
tor. Twenty-four hours later, the cells were trypsinized and re-cultured
in 24-well plates, and after an additional 24 h, the cells were assayed
for cAMP content (as a measure of AC activity) as described below.
Transfection e⁄ciencies were normally in the range of 40^80%, as
determined by transfection with pXMD1-gal and staining for L-galac-
tosidase activity [11].
2.4. AC assay
The assay was performed in triplicate as described previously
[10,11]. In brief, cells cultured in 24-well plates were incubated for
2 h with 0.25 ml/well of fresh growth medium containing 5 WCi/ml
of [3H]adenine, and then washed three times with 0.5 ml/well of
DMEM containing 20 mM HEPES (pH 7.4) and 0.1 mg/ml bovine
serum albumin (BSA). This medium was replaced with 0.5 ml/well of
DMEM containing 20 mM HEPES (pH 7.4), 0.1 mg/ml BSA and the
phosphodiesterase inhibitors IBMX (0.5 mM) and RO-20-1724
(0.5 mM). AC activity was stimulated by the addition of either
1 WM FS (for the activation of AC in CHO cells or of AC-V in
transfected COS cells), 1 WM ionomycin (for the stimulation of the
Ca2-dependent AC-I in COS cells transfected with this isozyme) or
0.1 WM TSH (for the stimulation of AC-II in transfected COS cells; in
this case, the cells were also cotransfected with the TSH receptor).
After 10 min incubation at room temperature, the medium was re-
moved and the reaction terminated by addition of perchloric acid
containing 0.1 mM unlabeled cAMP, followed by neutralization,
and the amount of [3H]cAMP was determined by a two-step column
separation procedure [10]. Chronic treatment was achieved by incu-
bating the cells for 4 h with the indicated concentrations of agonists,
followed by agonist withdrawal (by quick removal of medium and
addition of fresh medium containing 1 WM of the opiate antagonist
naloxone) and the addition of the appropriate AC stimulator (see
above) to assay cAMP accumulation. The incubation with
[3H]adenine took place during the last 2 h of the chronic exposure.
Uptake of [3H]adenine into the cells was not a¡ected by the chronic
agonist treatments.
Statistical analysis of the data was performed using the Student’s
t-test. Curve ¢tting and calculation of EC50 and IC50 were done by
non-linear regression using the GraphPad software package (ISI Soft-
ware, Philadelphia, PA, USA).
3. Results
3.1. E¡ects of acute and chronic morphine and morphine
glucuronides on AC activity
Dose^response curves for the e¡ects of acute and chronic
agonist exposures on AC activity in CHO cells are depicted in
Fig. 2. Signi¢cant inhibition of FS-stimulated cAMP accumu-
lation was observed in cells acutely treated with morphine or
morphine-6-glucuronide. Both materials showed similar ef-
fects on AC inhibition with IC50 values of 92 þ 9 nM and
71 þ 25 nM, respectively (Fig. 2a). No signi¢cant inhibition
was observed for morphine-3-glucuronide.
We have previously shown that chronic exposure to mor-
phine followed by removal of the agonist by extensive wash or
the addition of the antagonist naloxone leads to AC super-
activation [9]. Fig. 2b shows that chronic treatment of CHO-W
cells by either morphine or morphine-6-glucuronide induces
AC superactivation. The level of superactivation is dependent
on the concentration of these ligands during the chronic ex-
posure prior to the agonist withdrawal. The EC50 values for
AC superactivation by these opiate agonists appear to be
similar to the IC50 values for inhibition: 127 þ 27 nM and
136 þ 56 nM, respectively. This indicates that exposure to
Fig. 1. The O-demethylation pathway by CYP2D6 of codeine and
dihydrocodeine to morphine and dihydromorphine, respectively.
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morphine, and to a lesser extent to morphine-6-glucuronide,
did not lead to marked desensitization of the MOR (see also
Fig. 2c,d). This is consistent with results obtained previously,
which showed that morphine does not cause signi¢cant desen-
sitization of the W-receptor [9,26]. Chronic exposure to mor-
phine-3-glucuronide did not induce AC superactivation, in
agreement with its negligible e¡ect on acute AC inhibition.
Taken together, these results indicate that like morphine,
morphine-6-glucuronide activates the MOR, leading to inhi-
bition of the endogenous AC in CHO cells upon acute acti-
vation, and to AC superactivation upon chronic treatment,
while morphine-3-glucuronide has no e¡ect on the W-receptor.
CHO cells contain a mixture of several AC isozymes which
may well be di¡erentially a¡ected by the treatment with the
various opiate ligands. In order to examine the e¡ect of mor-
phine and its glucuronides on the various AC isozymes, we
employed the COS-7 cell system, which readily allows transi-
ent transfection of the MOR together with the desired AC
isozymes. Moreover, the endogenous AC in COS is not
strongly a¡ected by either acute or chronic agonist exposure
[10], allowing the analysis of the e¡ect of exogenous AC iso-
zymes.
Three types of AC isozymes, representing the three major
classes of AC isozymes according to their properties and se-
quence homologies, were studied. All these AC isozymes can
be stimulated by GKs, although they di¡er in their response to
Ca2 and GLQ . The three classes of AC isozymes were repre-
sented here by: AC-I, which, like AC-VIII, is stimulated by
Ca2/calmodulin; AC-V, which, like AC-VI, is inhibited by
Ca2 ions, stimulated by FS and inhibited by GLQ ; and AC-II,
which is similar to AC-IV and AC-VII, and is stimulated by
GLQ subunits in the presence of activated GKs [20,21,27,28].
The choice of these particular isozymes was also based on
the fact that these are the only three AC isozymes whose
mRNAs are expressed at high levels in the rat brain [20].
Due to the di¡erences between them, the three AC isozymes
were stimulated using three types of stimulants. The Ca2
ionophore ionomycin was used to activate AC-I, FS to acti-
vate AC-V and Ks activation (via activation of the TSH re-
ceptor cotransfected into the COS cells) was used to activate
AC-II.
The experiment presented in Fig. 2c shows that AC-V in
transfected COS cells is dose-dependently inhibited by acute
activation with morphine or morphine-6-glucuronide, with
IC50 values of 69 þ 22 nM and 129 þ 33 nM, respectively, val-
ues similar to those obtained with CHO cells. On the other
hand, morphine-3-glucuronide had no signi¢cant e¡ect on
AC-V. Similarly, chronic activation of the W-receptor by mor-
phine or morphine-6-glucuronide led to a dose-dependent AC
superactivation with EC50 of 122 þ 30 nM and 450 þ 100 nM,
respectively, while no superactivation was observed with mor-
phine-3-glucuronide.
Fig. 3 compares the e¡ect of acute and chronic opiate ex-
posures on AC-V vs. AC-I and AC-II. Acute activation of the
MOR by either morphine or morphine-6-glucuronide led to
inhibition of the stimulated activity of both AC-V and AC-I,
albeit much less strongly for the latter, while chronic activa-
tion of the MOR with either agonist followed by agonist with-
drawal led to superactivation of both of these isozymes (Fig.
3a,b). Again, the superactivation was much stronger with AC-
V. Neither acute nor chronic application of morphine-3-glu-
curonide had signi¢cant e¡ects on the activities of these two
AC isozymes.
Stimulation of AC-II by 0.1 WM TSH led to a large increase
in cAMP accumulation as compared to the basal level (see
legend to Fig. 3). However, in contrast to AC-I or V, acute
exposure of cells transfected with AC-II to either morphine or
morphine-6-glucuronide induced a signi¢cant increase in AC-
II activity (Fig. 3c), a result similar to the observations made
earlier with several other Gi=o-coupled receptor agonists
Fig. 2. Dose^response of acute and chronic treatment with morphine and morphine glucuronides on AC activity in CHO cells and on AC-V
activity in transfected COS-7 cells. FS-stimulated AC activity was determined (a,b) in CHO-W cells and (c,d) in COS cells transfected with the
cDNAs of AC-V and of the MOR. These CHO-W cells (a) or COS cells (c) were treated acutely (during the 10 min AC assay) with various
concentrations of morphine-3-glucuronide (b), morphine-6-glucuronide (8) or morphine (E). These CHO-W cells (b) or COS cells (d) were
treated chronically for 4 h with the opiate agonists followed by withdrawal (by a rapid wash and addition of 1 WM naloxone) just prior to the
assay of FS-stimulated AC activity. 100% represents the control FS-stimulated cAMP accumulation observed in the absence of opiate agonists
(a, b: 1182 þ 96 cpm; c, d: 7175 þ 632 cpm of [3H]cAMP). Data represent the means þ S.E.M. of three experiments.
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[7,11,29,30]. Moreover, following withdrawal from chronic
agonist treatment, not only was no superactivation of this
isozyme apparent, but a reduction in the activity of AC-II
was actually observed. As observed with AC isozymes I and
V, morphine-3-glucuronide had no signi¢cant e¡ect on AC-II
activity when applied either acutely or chronically.
3.2. Di¡erential e¡ects of 3-substituted and 3-unsubstituted
opiates on the regulation of AC activity
We investigated the e¡ects on AC activity of acute and
chronic treatment with several 3-substituted opiates (all at
1 WM) and their corresponding unsubstituted derivatives in
CHO cells stably transfected with the W-receptor. Codeine
and dihydrocodeine (which di¡er from morphine and dihy-
dromorphine by being methylated at the 3 position) showed
only minute inhibition after acute treatment and minute acti-
vation of AC after chronic treatment in comparison with the
unmethylated compounds morphine and dihydromorphine
(Fig. 4). A similar result was obtained with 3-ethylmorphine
(where an ethyl group replaced the methyl group of codeine).
These results demonstrate that like in morphine-3-glucuro-
nide, substitution at the 3P OH position of morphine or dihy-
dromorphine markedly reduces the activity of the opiate li-
gand.
4. Discussion
The results presented here indicate that morphine-6-glucu-
ronide parallels the e¡ects of morphine upon both acute and
chronic administration for di¡erent AC isozymes. Morphine-
6-glucuronide is one of the major metabolites of morphine,
and has demonstrated analgesic e¡ects in both animal and
human studies. While in animal studies morphine-6-glucuro-
nide presented superior analgesic e¡ects compared to mor-
phine, the analgesic e¡ects in humans are still contradictory
[31]. Osborne et al. [32] observed analgesic e¡ects of mor-
phine-6-glucuronide in cancer patients su¡ering severe pain,
while in a single-dose study in healthy volunteers, morphine-6-
glucuronide did not show any analgesic e¡ect [33]. As mor-
phine-6-glucuronide is rather hydrophilic compared to mor-
phine, its penetration via the blood^brain barrier might be
impaired and therefore, an e¡ective concentration of the
drug at the receptor within the central nervous system might
not have been achieved [34]. Concerning binding to the
W-receptor, morphine-6-glucuronide has shown an a⁄nity
comparable to that of morphine [13,15,16]. Our results are
in agreement with these binding studies, as morphine-6-glu-
curonide presents comparable results to morphine in both the
inhibition and superactivation of transfected AC-V, as well as
of the endogenous AC of CHO cells. These results, however,
are not able to explain the increased physical dependence after
chronic treatment of mice with morphine-6-glucuronide com-
pared to morphine, as observed by Frances et al. [15].
In this regard, recent studies suggest a new and speci¢c
binding site for morphine-6-glucuronide, heroin and 6-acetyl-
morphine [19]. Moreover, it was recently shown using MOR-1
knockout mice that heroin and morphine-6-glucuronide retain
analgesic e¡ects in mice lacking exon 1 of the MOR-1 gene,
Fig. 3. Acute and chronic MOR activation by morphine and mor-
phine glucuronides di¡erentially regulates the activity of various AC
isozymes. COS-7 cells were transfected with the cDNAs of the indi-
cated AC isozymes together with the cDNAs of the MOR and, in
the case of AC-II, also of the TSH receptor. Acute, the cells were
treated with 1 WM opiate for the 10 min of the AC assay; Chron-
ic+withdrawal, the cells were treated with 1 WM opiate for 4 h fol-
lowed by its withdrawal and immediate AC assay. (a) AC-V was
stimulated with 1 WM FS, (b) AC-I was stimulated with 1 WM iono-
mycin and (c) AC-II was stimulated with 0.1 WM TSH. These stim-
ulations increased AC activity by 5.4-, 2.0- and 6.8-fold, respec-
tively, compared to unstimulated AC activity (demonstrating
expression of the transfected AC molecule). M, morphine; M-3-G,
morphine-3-glucuronide; M-6-G, morphine-6-glucuronide. cAMP ac-
cumulation observed under these stimulating conditions (in the ab-
sence of morphine or morphine glucuronides) was de¢ned as 100%
(a, 6004 þ 384 cpm; b, 1853 þ 188 cpm; c, 9929 þ 696 cpm). Data
represent the means þ S.E.M. of triplicate determinations of a repre-
sentative experiment. *P6 0.05, **P6 0.01 vs. control.
Fig. 4. E¡ects of acute and chronic treatment with di¡erent 3-sub-
stituted and 3-unsubstituted opiates on AC activity in CHO-W cells.
FS-stimulated AC activity of CHO-W cells was determined following
acute treatment with 1 WM of the indicated opiates, or after 4 h
chronic treatment followed by agonist withdrawal. COD, codeine;
M, morphine; DHC, dihydrocodeine; DHM, dihydromorphine;
ETM, ethylmorphine. FS-stimulated cAMP accumulation in the ab-
sence of opiates is represented as 100% (1125 þ 82 cpm of
[3H]cAMP). Data represent the means þ S.E.M. of triplicate determi-
nations of a representative experiment out of three experiments
which gave similar results. *P6 0.02 vs. control.
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while the analgesia by morphine was lost. However, mor-
phine, heroin and morphine-6-glucuronide were without e¡ect
in the exon 2 MOR-1 de¢cient mice [18]. According to these
results, it was hypothesized that morphine-6-glucuronide, her-
oin and 6-acetylmorphine bind with high a⁄nity and speci¢c-
ity to a novel W-receptor subtype [18,19]. Future studies are
needed to investigate the role of chronic exposure to mor-
phine-6-glucuronide and heroin on this new W-receptor sub-
type, and whether it leads to AC superactivation.
As previously shown with morphine, the 6-glucuronide in-
hibited AC-V and AC-I, and stimulated AC-II, while reverse
modulation of these AC isozymes was observed after chronic
opiate exposure. This is important, as di¡erent parts of the
brain di¡er in their isozyme distribution pattern, thus leading
to a di¡erent pro¢le of AC modulation by the opiates in
di¡erent brain regions. For example, it has been shown that
opioid receptor activation can stimulate AC activity in the rat
olfactory bulb [35], while opiates are inhibitory in most other
parts of the brain.
Using CHO cells transfected with the MOR, we examined
the e¡ects of di¡erent opiates on AC activity after acute and
chronic treatment. We found that opiates substituted in posi-
tion 3, such as morphine-3-glucuronide, codeine, dihydroco-
deine and 3-ethylmorphine, presented neither signi¢cant inhi-
bition after acute treatment nor pronounced superactivation
after chronic opiate administration. This result is in agreement
with binding studies showing that substitution on the free
phenolic group (i.e. position 3) of morphine causes a large
decrease in binding to the MOR [36]. In contrast to these
3-substituted materials, the corresponding non-substituted
opiates, morphine and dihydromorphine, exhibit signi¢cant
inhibition after acute treatment and superactivation after
chronic treatment of the endogenous AC in CHO cells.
Morphine also displayed this for individual AC isozymes
from the AC-I/VIII and AC-V/VI families [11].
Codeine and dihydrocodeine are among the most widely
used and abused prescription drugs (analgesics, cough syrups),
and although they have been classi¢ed as weak opiates, they
have been shown to lead to addiction and withdrawal symp-
toms. Moreover, these drugs are rising steadily in the drug
abuse rankings [22,23]. Codeine and dihydrocodeine, however,
can be transformed into morphine and dihydromorphine by
CYP2D6 [25,37,38], an enzyme expressed in liver as well as in
brain [39]. However, CYP2D6 presents a genetic polymor-
phism, in that 7^10% of the Caucasian population do not
express a functional enzyme [40] and can therefore not form
more than trace amounts of morphine or dihydromorphine
from codeine or dihydrocodeine, respectively [24,25]. Clinical
studies by us and others with healthy volunteers showed that
only those with functional CYP2D6 activity obtained analge-
sic e¡ects from codeine administration. This suggests that the
analgesic e¡ects obtained upon codeine administration are
mediated by the metabolite morphine, rather than by codeine
itself [24,38]. Our current results show that codeine and dihy-
drocodeine do not signi¢cantly a¡ect AC activity. These re-
sults suggest that the metabolically formed morphine and di-
hydromorphine, rather than the weak opiates codeine and
dihydrocodeine themselves, may lead to the analgesic e¡ects
as well as to the development of addiction and withdrawal
symptoms. Furthermore, these results may explain the indi-
vidual di¡erences in the development of addiction symptoms
by codeine and dihydrocodeine as a result of the genetic poly-
morphism of the metabolizing enzyme, CYP2D6. These con-
siderations are supported by a recently published study, which
demonstrates that individuals lacking CYP2D6 activity are
protected against oral codeine, oxycodone and hydrocodone
dependence [41]. As a consequence, subjects addicted to weak
opiates have been successfully treated with £uoxetin, an in-
hibitor of CYP2D6, resulting in a reduction of the usage of
these weak opiates [41]. Taken together, our results help to
understand the development of addiction and withdrawal
symptoms following the use of weak opioid receptor agonists
such as codeine and dihydrocodeine, supporting the hypoth-
esis that the metabolic transformation of weak opiates to
stronger opiates (e.g. morphine and dihydromorphine) is an
important step in the devolopment of addiction to these
drugs.
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